FDA warns J & J on insulin pumps

Share this article:

Johnson & Johnson could face penalties for not reporting incidents where insulin pumps have failed, the Food and Drug Administration has warned.

In a Dec. 27 letter to the company's Animas Corp. unit, the FDA says the company should have reported incidents where the device failure may have caused injury, including diabetic ketoacidosis. It also said Animas failed to create a system for making adequate medical device reports.

The letter, which was made public last week, followed a site visit in 2011. It warns “failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.”

Diabetes is among the top ten leading causes of death in the U.S. Insulin pumps deliver rapid- or short-acting insulin throughout the day via a catheter rather than require a person or caregiver to do periodic injections.



Share this article:

More in News

Rape investigation blocked by nursing home's HIPAA concerns, authorities say ...

Florida authorities say a nursing home is citing privacy laws to impede the investigation of a possible resident rape, according to local news reports.

Jury hands down $14 million negligent care verdict to 'send message' to nursing homes

Jury hands down $14 million negligent care verdict ...

A Massachusetts jury has awarded $14 million to the family of a nursing home resident who died due to a pressure ulcer, dehydration and other conditions linked to negligent care, ...

CCRC executive director salaries hold steady, therapy directors get boost

Continuing care retirement community executive director salaries have barely increased in the past year, while therapy and rehabilitation directors received a boost, a new report shows. The average salary for a therapy and rehab director is currently $95,905.